OBJECTIVE: Computerized neuropsychological testing may facilitate screening for cognitive impairment in systemic lupus erythematosus (SLE). This study was undertaken to compare patients with SLE, patients with rheumatoid arthritis (RA), and patients with multiple sclerosis (MS) with healthy controls using the Automated Neuropsychological Assessment Metrics (ANAM). METHODS: Patients with SLE (n = 68), RA (n = 33), and MS (n = 20) were compared with healthy controls (n = 29). Efficiency of cognitive performance on 8 ANAM subtests was examined using throughput (TP), inverse efficiency (IE), and adjusted IE scores. The latter is more sensitive to higher cognitive functions because it adjusts for the impact of simple reaction time on performance. The results were analyzed using O'Brien's generalized least squares test. RESULTS: Control subjects were the most efficient in cognitive performance. MS patients were least efficient overall (as assessed by TP and IE scores) and were less efficient than both SLE patients (P = 0.01) and RA patients (P < 0.01), who did not differ. Adjusted IE scores were similar between SLE patients, RA patients, and controls, reflecting the impact of simple reaction time on cognitive performance. Thus, 50% of SLE patients, 61% of RA patients, and 75% of MS patients had impaired performance on >or=1 ANAM subtest. Only 9% of RA patients and 11% of SLE patients had impaired performance on >or=4 subtests, whereas this was true for 20% of MS patients. CONCLUSION: ANAM is sensitive to cognitive impairment. While such computerized testing may be a valuable screening tool, our results emphasize the lack of specificity of slowed performance as a reliable indicator of impairment of higher cognitive function in SLE patients.
OBJECTIVE: Computerized neuropsychological testing may facilitate screening for cognitive impairment in systemic lupus erythematosus (SLE). This study was undertaken to compare patients with SLE, patients with rheumatoid arthritis (RA), and patients with multiple sclerosis (MS) with healthy controls using the Automated Neuropsychological Assessment Metrics (ANAM). METHODS: Patients with SLE (n = 68), RA (n = 33), and MS (n = 20) were compared with healthy controls (n = 29). Efficiency of cognitive performance on 8 ANAM subtests was examined using throughput (TP), inverse efficiency (IE), and adjusted IE scores. The latter is more sensitive to higher cognitive functions because it adjusts for the impact of simple reaction time on performance. The results were analyzed using O'Brien's generalized least squares test. RESULTS: Control subjects were the most efficient in cognitive performance. MS patients were least efficient overall (as assessed by TP and IE scores) and were less efficient than both SLE patients (P = 0.01) and RA patients (P < 0.01), who did not differ. Adjusted IE scores were similar between SLE patients, RA patients, and controls, reflecting the impact of simple reaction time on cognitive performance. Thus, 50% of SLE patients, 61% of RA patients, and 75% of MS patients had impaired performance on >or=1 ANAM subtest. Only 9% of RA patients and 11% of SLE patients had impaired performance on >or=4 subtests, whereas this was true for 20% of MS patients. CONCLUSION: ANAM is sensitive to cognitive impairment. While such computerized testing may be a valuable screening tool, our results emphasize the lack of specificity of slowed performance as a reliable indicator of impairment of higher cognitive function in SLE patients.
Authors: Tom N Tombaugh; Laura Rees; Peter Stormer; Allyson G Harrison; Andra Smith Journal: Arch Clin Neuropsychol Date: 2006-10-27 Impact factor: 2.813
Authors: J A Wilken; R Kane; C L Sullivan; M Wallin; J B Usiskin; M E Quig; J Simsarian; C Saunders; H Crayton; R Mandler; D Kerr; D Reeves; K Fuchs; C Manning; M Keller Journal: Mult Scler Date: 2003-03 Impact factor: 6.312
Authors: Laura Plantinga; Benjamin D Tift; Charmayne Dunlop-Thomas; S Sam Lim; C Barrett Bowling; Cristina Drenkard Journal: Arthritis Care Res (Hoboken) Date: 2018-08-27 Impact factor: 4.794
Authors: Hermine I Brunner; Marisa S Klein-Gitelman; Frank Zelko; Erin C Thomas; Jessica Hummel; Shannen M Nelson; Jennifer Huggins; Megan L Curran; Tresa Roebuck-Spencer; Dean W Beebe; Jun Ying Journal: Arthritis Care Res (Hoboken) Date: 2013-03 Impact factor: 4.794
Authors: Ashwaq AlE'ed; Patricia Vega-Fernandez; Eyal Muscal; Claas H Hinze; Lori B Tucker; Simone Appenzeller; Brigitte Bader-Meunier; Johannes Roth; Vicenç Torrente-Segarra; Marisa S Klein-Gitelman; Deborah M Levy; Tresa Roebuck-Spencer; Hermine I Brunner Journal: Arthritis Care Res (Hoboken) Date: 2017-08-29 Impact factor: 4.794
Authors: Ghaydaa A Shehata; Yasser Mb Elserogy; Hossam Eddin K Ahmad; Mohamed I Abdel-Kareem; Ashraf M Al-Kabeer; Mohamed M Rayan; Mohamed Es Abd El-Baky Journal: Int J Gen Med Date: 2011-04-20
Authors: Chris Edgar; Peter J Jongen; Evert Sanders; Christian Sindic; Sophie Goffette; Michel Dupuis; Philippe Jacquerye; Daniel Guillaume; Regine Reznik; Keith Wesnes Journal: BMC Neurol Date: 2011-06-07 Impact factor: 2.474